Moving forward in the face of economic adversity, the first anniversary of shengnuo biotechnologylisting!

Coinciding with the first anniversary of SinoBio’s listing on the Science and Technology Innovation Board, the editor will take stock and share with colleagues, partners and media colleagues on the development of our company since the listing for one year.

New track layout

The second is the layout of our new track.

As we all know, shengnuo biotechnology has been deeply engaged in peptide APIs, preparations, and CDMOs for more than 20 years. In the one year of listing, shengnuo biotechnology has made two important decisions: to expand the industry to the competition of peptide medical beauty and new crown special drugs. road!

Sirnatech has been assigned the exclusive right to use the clinical approval and patent of an anti-coronavirus peptide drug in China

On March 29 this year, the resolution of the thirteenth meeting of the third board of supervisors of the company was announced, and all rights and interests related to the patent rights of the AOD53724 project owned by Aoda Bio were transferred in China (the clinical approval has not yet been obtained), Since then, it has marked the layout of the R&D business of shengnuo biotechnologynew crown specific drugs. This patent will be used to develop a nasal spray-type peptide specific drug for the new crown. The project strives to apply for China’s clinical approval before the end of 2022. It is estimated that it will take 2-3 years to complete the project, and the total investment is expected to be RMB 175 million.

On March 2 this year, the company’s board of directors reviewed and approved the foreign investment capital increase proposal. Shengrong Netac, a wholly-owned subsidiary of Shengnuo Bio, will subscribe Guangzhou Shengjing Shangmei Biotechnology Co., Ltd. (hereinafter referred to as Guangzhou Shengjing) for RMB 490.00 at RMB 24.50 million. The new registered capital of 10,000 yuan accounts for 49% of the total share capital of Guangzhou Shengjing after the capital increase.

The capital increase agreement has been signed and the capital contribution will be completed on March 11, 2022. Guangzhou Shengjing’s main business is: providing a full range of peptide medical beauty products and services, and has its own brand products and formulas. shengnuo biotechnologylogical will also provide raw materials for it in the early stage.

The other is the subscription of the newly added registered capital of Chengdu Gechun Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as Chengdu Gechun). Shengrong Netac, a wholly-owned subsidiary, subscribed for an additional registered capital of RMB 225,000 of Chengdu Gechun Bio-Pharmaceutical Co., Ltd. (hereinafter referred to as Chengdu Gechun) for RMB 15,000,000, accounting for 13.0434% of the total share capital of Chengdu Gechun after the capital increase.

Chengdu Gechun’s main business is: research and development of APIs, pharmaceutical intermediates, cosmetic raw materials, and food additives; research on authentic Chinese medicinal materials, preclinical research on various innovative natural medicines, and establishment of a library of plant monomer compounds; Natural product intermediates, chemical components of traditional Chinese medicines, reference substances of traditional Chinese medicines, natural product extracts, etc. for high-purity new drug research and development.

The two new carriages are the perfection of the shengnuo biotechnology industrial chain and the expansion of the research and development field. Under the layout of the new track, it will further enhance the competitive advantage of shengnuo biotechnology. From the perspective of industrial value, the new track is also an important performance growth point for shengnuo biotechnology in the future!

At present, related projects are progressing in an orderly manner, and I believe there will be new good news soon!

Production line expansion

Of course, there is another big event – the expansion of the production line for APIs!

As the important core business of shengnuo biotechnology, the APIs we produce have been in short supply for a long time. After expansion, our API production lines will reach 8, thus doubling the production capacity and meeting more market demands. The expansion project is expected to be completed in June and can be officially put into use in the second half of the year.

The first is the 2021 annual report. As a “barometer” of the company’s operating status, our 2021 annual report is very stable, with an operating income of 387 million yuan, a year-on-year increase of 2.05%, and a year-on-year increase of 2.09% in net profit. Secondly, this year’s Q1 quarterly report The data is also very bright! Although revenue declined year-on-year, net profit increased by 22.64% year-on-year! (Please poke me to read the annual report in one picture)

This data is inseparable from the joint efforts of all colleagues of shengnuo biotechnology. Under the impact of the epidemic, we have withstood the pressure and achieved hard-won results, which also gave us full confidence in our future development.

From this point of view, our growth experience of shengnuo biotechnologylogical has gradually expanded from the initial peptide API, preparations, and CDMO as the core business, and gradually expanded to the current dual-line layout of medical beauty + new crown specific drugs, completing a gorgeous transformation of gradual upgrades. In the future, shengnuo biotechnology will also uphold its original intention, forge ahead, and make every effort to contribute to the prosperity and development of China’s peptide industry.

After a long journey, the future is still promising!

Other Polypeptide APIs Products

peptide synthesis companies

Polypeptide APIs Products
Beauty peptides
Chinese cGMP APIs
Mexico Registered APIs
Research Peptide APIs for Regulatory Market
Polypeptide Preparation
Kaijie bio medicine Peptide APIs